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Summary. Vitamin D deficiency is a main risk factor for cardiovascular disease. Low serum vitamin D can 
increase blood pressure and weight in person. A case–control study was conducted on 69 matched pairs, aged 
40-60 years. Vitamin D was measured by Chemi-luminescence immunoassay method. There was signifi-
cant difference in serum 25- Hydroxy vitamin D between groups of study (P= 0.0001). The mean ± SD of 
25-Hydroxy vitamin D in prinzmetal angina was 12.16 ± 5.21 and in healthy persons was 23.44 ± 2.52 ng/
ml. Between vitamin D and waist circumference there was significant association in prinzmetal patients (p= 
0.04, ß= 0.236). There was not significant relation between vitamin D with blood pressure and BMI in study 
participants (P≥0.05). Vitamin D can effect on obesity in prinzmetal angina patients. 
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O r i g i n a l  a r t i c l e
Introduction
Prinzmetal variant angina (PVA) is an unusual 
syndrome of cardiac pain secondary to myocardial is-
chemia, which is not intensified by physical exertion 
or emotional stress, and is associated with transient ST 
(one section of Electrocardiogram) segment elevation 
(1). Many studies indicated that vitamin D deficiency 
is a main risk factor for cardiovascular disease (CVD), 
because the cardiac tissue has vitamin D receptor 
(VDR). Since 2008, more than 30 cohort studies have 
been published, with meta-analyses of their results 
showing that low baseline levels of blood 25-hydroxy-
vitamin D (25(OH)D) predict increased risk of CVD 
and all-cause mortality during follow-up. Hyperten-
sion (HTN) is a chronic condition that can lead to re-
nal disease, CVD, stroke, and mortality (2). Moreover, 
previous cross-sectional and cohort studies have shown 
an inverse association between 25(OH)D concentra-
tion and blood pressure (3). A previous meta-analysis 
including eight prospective studies reported that the 
level of 25(OH)D was inversely associated with the 
incidence of HTN (RR: 0.70; 95% CI: 0.58e0.86) (4). 
Obesity is one of main risk factor for cardiovascular 
disease. In addition, several prospective studies report-
ed that low 25(OH)D plasma levels may determine 
the incidence of obesity (5). The reported prevalence of 
vitamin D deficiency in obese individuals ranges from 
21% to 87% (5, 6) depending on the severity of obe-
sity, country of residence, ethnicity, skin pigmentation, 
clothing customs, and use of vitamin supplementation. 
Recently, a large genetic study reported that genes as-
sociated with reduced 25(OH)D levels have very small 
effects on obesity (7). Despite importance of coronary 
heart diseases in Ardebil, no risk factor study has ever 
been conducted; therefore, we decided to conduct a 
case-control study to investigate the hypothesis that 
whether there is any relation between serum vitamin D 
with blood pressure and obesity in prinzmetal angina 
patients.
Material and method
A case-control study was conducted on 69 
matched pairs, aged 40-60 years, and persons that 
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referred to Emam Khomeini hospital of Ardebil. To 
recruit controls, 100 households were visited and 70 
eligible controls (70% of eligible controls) agreed to 
participate in the study. Control group was sought for 
each case, frequency matched to the case group based 
on age and gender. Control group was selected ran-
domly from households of the same region depending 
of being visited by health professionals. The aims and 
study protocol were explained to the both groups and 
a written consent was taken prior to filling a question-
naire.  Exclusion criteria included: Persons that had 
other metabolic diseases, were pregnant, or had used 
calcium or vitamin D supplement in the past 6 month. 
In the study start, a general questionnaire about per-
sons’ health condition and confounder risk factors was 
completed to assess. Anthropometric parameters in-
cluding height, weight and body mass index (BMI) 
at the baseline and end of the study were measured. 
Using a pretested questionnaire, a trained interviewer 
collected information, which included demographic 
data, job, age, medication use, and education level. 
Arterial blood pressure was measured between 7:00 
a.m. and 11:00 a.m. after a rest of at least 5 min via a 
sphygmomanometer with a cuff and a stethoscope to 
detect the Korotkoff sound. Each person was asked to 
take a seated position, and their arm was supported 
at heart level. The first sound was defined as systolic 
blood pressure (SBP), while the last sound was defined 
as diastolic blood pressure (DBP).
Serum 25- Hydroxyl vitamin D assessment
Serum 25-Hydroxyl vitamin D was determined 
by Chemi-luminescence immunoassay method. This 
automated immunoassay is the previous version of the 
new follow-up IDS-iSYS 25(OH)DS CLIA as listed 
below. It is based on chemiluminescence technology. 
The assay was performed on the IDS-iSYS Multi-
Discipline Automated Analyzer. 10 µL of serum ali-
quots were automatically pipetted and subjected to a 
pre-treatment step with NaOH (part of the reagent 
used for CLIA and ELISA methods) to denature the 
DBP inside the IDS-iSYS Multi-Discipline Auto-
mated Analyzer. The extraction procedure of 25(OH)
D from the DBP was followed by analysis. This assay 
is not aligned to the NIST SRM (NIST, Gaithersburg, 
Maryland). The measurement range of this assay is 
5-140 ng/mL (information of the manufacturer). The 
IDS-iSYS 25(OH)D control set (IS-2730) (Immu-
nodiagnostic Systems Ltd, Boldon, United Kingdom) 
was used for quality control (QC) (8).
Statistics analysis
To correlate variables with normal and non-nor-
mal distribution, Pearson’s and Spearman’s correlations 
respectively were used. Normally distributed continu-
ous variables are reported as the mean ± SD. Pearson 
Chi-Square test was used to compare qualitative vari-
ables, independent sample t-test was used to compare 
quantitative variables means. Statistical analyses were 
performed using SPSS version 16.0. For relation eval-
uating vitamin D with obesity and blood pressure liner 
regression was used. In all of analyses p< 0.05 was sig-
nificant.
Results
The characteristics of the sample population are 
summarized in Table 1. No significant differences be-
tween groups were observed in age, weight, height, age 
and sex (p>0.05). The prinzmetal angina patients had 
higher values for blood pressure. Systolic and diastolic 
blood pressure mean± SD in prinzmetal angina pa-
tients was 13.60± 0.56 and 8.98 ± 0.46. There was sig-
nificant difference between groups in SBP and DBP 
(p<0.05).
Table 2 indicates vitamin D status in prinzmetal an-
gina patients and health persons. There was significant 
difference in serum 25- Hydroxy vitamin D between 
groups of study (p= 0.0001). Vitamin D status in 2.9% 
of patients and health persons was normal.
Table 3 indicates relation of vitamin D with blood 
pressure and obesity in study participants. There was 
significant relation between serum vitamin D with 
Waist circumference in prinzmetal angina patients 
(p= 0.04, ß= 0.236). There was not significant relation 
between vitamin D with blood pressure and BMI in 
study participants (P≥0.05).
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Discussion
In our results there was significant association in 
serum 25-Hydroxy vitamin D between patients and 
healthy persons. About 3% of prinzmetal patients had 
normal vitamin D status, 5.9% had insufficient vitamin 
D, 58.8% had moderate vitamin D deficiency, 32.4% 
had severe vitamin D deficiency. Just 2.9% of healthy 
persons had moderate vitamin D deficiency. Kienre-
ich in one study indicated that there is a significant 
association between low vitamin D level with cardio-
vasulare disease prevalence (9). Possible mechanisms 
underlying this association include increased inflam-
mation, renin–angiotensin system upregulation, in-
sulin resistance, altered lipid metabolism, and altered 
vascular smooth muscle growth and function that lead 
to hypertension, diabetes, dyslipidemia and athero-
sclerosis (10). For first in the present study, we report-
ed the relation between serum 25-Hydroxy vitamin 
D with blood pressure in prinzmetal angina patients 
and health persons; there was not any relation between 
vitamin D with blood pressure. Evidence from ran-
domised controlled trials to assess the effectiveness of 
vitamin D supplementation in reducing blood pressure 
have not provided consistent evidence of a benefit (11). 
In subgroup analyses done within meta-analyses of 
these trials (12, 13), some reductions in diastolic blood 
pressure were reported for participants with hyperten-
sion or cardiometabolic diseases, and when studies had 
used higher doses were compared with those that used 
lower doses of vitamin D (14). Although the inves-
tigators of one study (15) reported dose-dependent 
reductions in systolic blood pressure after 3 months 
of supplementation with 1000 IU, 2000 IU, and 4000 
IU of vitamin D per day (0·66, 3·4, and 4·0 mm Hg, 
respectively), no effect was seen in another trial  (16). 
Table 1. Baseline Characteristic of the study population
Variables Case group Control group Pv* 
 (n=34) (n=35)
Age (y) 51.26± 0.86 51.20 ± 0.96 0.356
Weight (kg) 88.30 ± 2.29 88 ± 2.60 0.390
Height (m) 1.70 ± 0.007 1.70 ± 1.006 0.410
BMI 26.25 ± 2.35 25.28 ± 2.05 0.084
Systolic blood pressure (mmHg) 13.60± 0.56 11.61 ± 0.93 0.039
Diastolic blood Pressure (mmHg) 8.98 ± 0.46 8.16 ±0.26 0.001
Sex(%) 
Male 50 50 0.079 
Female 50 50
Waist circumference   (cm) 92.15± 5.80 84.93± 7.43 0.001
*:based on independent sample T - test
Table 2. Serum 25 Hydroxy vitamin D statue in study partici-
pants 
Vitamin D case group control group p
Mean± SD (ng/ml) 12.16 ± 5.21 23.44 ± 2.52 0.0001
30≤  (%) 1(2.9) 1(2.9)
20-30 2(5.9) 33(94.3)   
10-20 20(58.8) 1(2.9)
10 11(32.4) 0
Table 3. Regression coefficients (B) from the linear model with 
25-Hydroxy vitamin D as independent variable
 Case group Control group 
 P ß P ß  
Systolic blood pressure 0.48 0.007 0.20 0.090
Diastolic blood pressure 0.09 0.229 0.08 0.682
BMI 0.36 -0.062 0.27 0.093
Waist circumference 0.04 0.236 0.085 0.22    
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Vitamin D metabolites could also exert antihyperten-
sive effects through various other molecular mecha-
nisms. Vitamin D is indirectly related to blood pres-
sure through its regulation of calcium absorption from 
the gut and its interaction with parathyroid hormone 
in the maintenance of calcium homeostasis. The reno-
protective and anti-inflammatory actions of vitamin D 
metabolites and their analogues suggest a possible role 
for vitamin D deficiency in cardiovascular morbidity 
and mortality in patients with chronic kidney disease. 
Furthermore, adipocyte inflammation has a crucial 
role in hypertension: in an in-vitro study, 1,25(OH)2D 
inhibited lipopolysaccharide-stimulated cytokine se-
cretion in two human adipocyte models through direct 
inhibition of nuclear factor-κB (17, 18) . Small sample 
size is one of the reasons of our different results. We 
did not measure the stress level in persons, this can 
be another reason for our different results. Our study 
indicated that there was significant relation between 
waist circumference with vitamin D in prinzmetal an-
gina patients, this relation was not significant in health 
persons. There was not significant relation between vi-
tamin D with body mass index. Low serum 25(OH)
D concentrations are inversely associated with insulin 
resistance and metabolic syndrome, especially in those 
who are overweight and obese. The exact molecular 
mechanisms at the origin of fatty acid oxidation re-
main to be identified VDR appears as a good candi-
date of such regulation. It would have been interest-
ing to verify whether this nuclear receptor is involved 
by using genetically modified mice. However, VDR/ 
mice are resistant to high fat diet-induced obesity (19) 
Gonzalez in one study indicated that  obese person 
had vitamin D dificiency comparioson with  person 
with normal weight (20). Vitamin D stimulates adi-
posity tissue cells so it can increase fat oxidation (21). 
To conclude, our data did not indicate any relation be-
tween serum vitamin D and blood pressure, body mass 
index, but there was relation between vitamin D with 
waist circumference in prinzmetal patients. Our sam-
ple size was small, we did not measure stress level, and 
these are our study limitations. Our results may not be 
generalizable to other racial/ethnic groups or may not 
be generalizable to others living indifferent geographi-
cal latitudes and altitudes.
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